- Our Company
- News & Events
- Contact Us
Check out Guardant Health Inc.’s new product website at guardant360cdx.com. Find out how our test can help treat at the speed of cancer. Guardant360 CDx is the first FDA-approved liquid biopsy for comprehensive genomic profiling of patients across all solid cancers, providing doctors with complete genomic results in 7 days from sample receipt in the laboratory to inform first-line treatment plans fast.
If you are a medical oncologist in Asia, Middle East or Africa, visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. If you have any queries, send us an email at firstname.lastname@example.org or contact us on WhatsApp: +65 8940 0360.
Guardant360®. Test. Take Action.